Now ideas for wellness

About Meiji

At a Glance

At a Glance

Get to know Meiji at a glance – from our core business to our most important numbers.

Pharmaceuticals

R&D

Medical needs are always diversifying – here's how Meiji is responding.

Pipeline

As of May 12, 2022

  • Clinical Trial
  • Japan
  • Outside of Japan

In-house drug discovery

In-house development

Infectious Diseases

FYE March 2022 FYE March 2023 FYE March 2024
ME1100 Arbekacin inhalation: [HABP/VABP] Phase Ib
OP0595 Nacubactam: [β-lactamase inhibitor] Phase I
with
β-Lactams
Phase III

More about our work in the field of infectious diseases:

LEARN MORE

Others

FYE March 2022 FYE March 2023 FYE March 2024
HBI-8000 Tucidinostat: [Relapsed or refractory Adult T-cell leukemia/lymphoma (ATLL)] *1 Approved
HBI-8000 Tucidinostat: [Relapsed or refractory peripheral T-cell lymphoma (PTCL)] *1 Applied Approved
ME3208 Belumosudil: [Chronic Graft Versus Host Disease] *2 Phase I Phase III
DMB-3115 Ustekinumab biosimilar: [Plaque psoriasis, Psoriatic arthritis, Crohn's disease, Ulcerative colitis] *3 PI Phase III
Phaseâ… 
ME3183: [Psoriasis/Selective PDE4 inhibitor] Phase I Phase II
HBI-8000 Tucidinostat: [Relapsed or refractory B-cell non-Hodgkin's lymphoma] *4 Phase Ib/II
DMB-3111 Trastuzumab biosimilar: [Breast cancer, Gastric cancer] *3 (P I finished)

*1 Development: HUYABIO International, LLC (USA)

*2 Development: Romeck Pharma, LLC

*3 Co-development: Dong-A Socio Holdings Co., Ltd. (South Korea)

*4 In-license: HUYABIO International, LLC (USA)

Vaccines

FYE March 2022 FYE March 2023 FYE March 2024
KD-370: [Pentavalent vaccine against diphtheria, tetanus, pertussis, polio, and haemophilus influenza type b] Phase III Applied Approve
Phase II
KD-414: [Inactivated vaccine against COVID-19] Phase I / II
Phase II / III
Phase II/III
(Pediatric
Clinical Trials)
Phase III
(Adults under 40) *5
KD-404: [Egg-derived inactivated whole virus influenza vaccine] *6 Phase
I / II
KD-382: [Quadrivalent vaccine against dengue fever] Phase I

*5 Multi-Regional Clinical Trials

*6 Cooperation: Hokkaido University

More about our work in the field of vaccines:

LEARN MORE

Blood Plasma Products

FYE March 2022 FYE March 2023 FYE March 2024
KD2-305: [Suppression of bleeding tendency in patients with blood coagulation factor VIII or factor IX deficiency who have coagulation factor inhibitors] Phase II / III Applied Approve
Extension study blank blank

More about our work in the field of blood plasma:

LEARN MORE

Veterinary Drugs

FYE March 2022 FYE March 2023 FYE March 2024
ME4136: [Injectable antibacterial drugs] Approved
ME4137: [Injectable antibacterial drugs for cattle use] Applied Approve
ME4137: [Injectable antibacterial drugs for swine use] Applied Approve
ME4406: [Feed additive] Apply
ME4204: [Oral anthelmintic] Expanded indication Approved
ME4618: [Anesthetic injection] Applied Approve
ME4624: [Vaccine] Approved
KD-395: [Vaccine for swine use] Applied Approve
KD-386: [Vaccine for swine use] Applied Approve

More about our work in the field of veterinary drugs:

LEARN MORE